The New England Journal of Medicine
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Biogen to acquire RayThera in $1bn deal
The acquisition will expand the company’s immunology pipeline
Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA
In the study, there were improvements in motor function as well as a slowing of neurodegeneration
Biogen agrees $850m felzartamab rights deal with TJ Biopharma
The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases
MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment
SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Biogen to acquire Apellis in $5.6bn deal
The deal will enhance Biogen’s growth portfolio in immunology and rare disease
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark
Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus
Therapies like topical steroids manage symptoms but there is currently no cure
Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s
Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients
Eisai submits new drug application for subcutaneous Leqembi in Japan
LEQEMBI is a treatment for early Alzheimer’s disease
Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment
The MHRA approval for IV dosing comes following positive results from the global phase 3 trial